US Opportunity Analysis: Comparing US Practice to CONQUEST Quality Standards (2011-2019)

- An observational, longitudinal, descriptive study for the CONQUEST programme
- Focused on a population of high-risk patients with diagnosed or potential COPD.
- Analysis sample was identified in 2019 and in each previous year back to 2011.
- Routinely collected primary care data was assessed over the relevant time frame for each outcome; the 12 months before or after 1 January of each study year.
- 2019 was chosen as the key year for the data as it provides the most up-to-date information prior to the COVID-19 pandemic.

CONQUEST

Collaboration On Quality Improvement Initiative
for Achieving Excellence in Standards of COPD Care.

Patterns of care in the management of high-risk COPD in the US (2011-2019): an observational study for the CONQUEST quality improvement program.

Margee Kerr, Yasir Tarabichi, Alexander Evans, Douglas Mapel, Wilson Pace, Victoria Carter, Amy Couper, M Bradley Drummond, Norbert Feigler, Alex Federman, Hitesh Gandhi, Nicola A Hanania, Alan Kaplan, Konstantinos Kostikas, Maja Kruszyk, Marije van Melle, Hana Müllerová, Ruth Murray, Jill Ohar, Michael Pollack, Rachel Pullen, Dennis Williams, Juan Wisnivesky, MeiLan K Han, Catherine Meldrum, David Price.

Lancet Regional Health – Americas. 2023. 24: 100546.

CONQUEST is conducted by Optimum Patient Care Global and the Observational and Pragmatic Research Institute and is co-funded by Optimum Patient Care Global and AstraZeneca

opc Global

Aims & Methods

CONQUEST Opportunity Analysis Study Design, Objectives & Underpinning Quality Standards (QS)

Annual, cross-sectional descriptive study assessing each country's clinical practices in the management of COPD relative to global & national standards, and the CONQUEST QS

Identification of target population

Assessment of disease & quantification of future risk

Follow up

Non-pharmacological & pharmacological intervention

CONQUEST
Collaboration On Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care.

Pullen et al. 2021. *Int J Chron Obstruct Pulmon Dis. 2021(6), 2301-2322*

USA Opportunity Analysis: Data Source & Study Populations



Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

Key US Results & Take Away Messages

USA Opportunity Analysis : Key Takeaway Messages

1. **Scope to enhance identification of those at high-risk of exacerbations & other adverse events**
2. **Opportunities to Assess & Diagnose Earlier**
3. **Opportunities to Provide Earlier Pharmacological & Non-pharmacological Intervention**
4. **Scope to Improve Consistency in EMR Coding**

Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

Takeaway Message 1 : Scope to enhance identification of those at high-risk of exacerbations & other adverse events



High-risk patients are those with COPD or potential COPD who have ≥2 moderate, or ≥1 severe exacerbations in the last 24 months, with at least 1 exacerbation occurring in the last 12 months

Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

Takeaway Message 2 : Opportunities to Assess & Diagnose Patients Earlier



2019 Data. Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

Takeaway Message 3 : Scope to Improve Consistency in EMR Coding



EMR: Electronic Medical Records; PEF: Peak Expiratory Flow. Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

Takeaway Message 3 : Scope to Improve Consistency in EMR Coding (2)

Already diagnosed
High-risk Cohort



2019 Data. Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

Takeaway Message 4 : Opportunities to Provide Earlier Pharmacological & Non-pharmacological Intervention



2019 Treatment Status for High-risk Undiagnosed



2019 Treatment Status for High-risk Newly & Already Diagnosed

Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

Conclusions from USA Data

Key Conclusion: Scope for Earlier Diagnosis, Improved Assessment & Treatment Optimisation

QS 1: Identification

QS 2: Assessment

QS 3&4: Optimization & Follow-up

Missed opportunities for **earlier diagnosis**

+

Newly Diagnosed, High-Risk patients are **not** adequately assessed or treated within 1 year

→

For Already Diagnosed patients, substantial scope to improve

- assessment
- treatment optimization

QS: CONQUEST Quality Standard. Kerr et al. *Lancet Regional Health – Americas.* 2023. 24: 100546. https://doi.org/10.1016/j.lana.2023.100546

CONQUEST
Quality Improvement Initiative for Achieving Excellence in Standards for COPD Care

For More Information on the Findings of the US Opportunity Analysis Manuscript

- View the full article here: https://doi.org/10.1016/j.lana.2023.100546

opc Global